This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
30 Citations 4 Q&As
5 Citations 12 Q&As
7 Citations 16 Q&As
Facts about Stromelysin-1.
.
Human | |
---|---|
Gene Name: | MMP3 |
Uniprot: | P08254 |
Entrez: | 4314 |
Belongs to: |
---|
peptidase M10A family |
CHDS6; EC 3.4.24; EC 3.4.24.17; matrix metallopeptidase 3 (stromelysin 1, progelatinase); matrix metalloproteinase 3 (stromelysin 1, progelatinase); Matrix metalloproteinase-3; MGC126102; MGC126103; MMP3; MMP-3; proteoglycanase; SL-1; STMY; STMY1MGC126104; STR1; Stromelysin 1; stromelysin-1; transin-1
Mass (kDA):
53.977 kDA
Human | |
---|---|
Location: | 11q22.2 |
Sequence: | 11; NC_000011.10 (102835801..102843609, complement) |
Secreted, extracellular space, extracellular matrix.
A recent article in Molecular Diagnostics features the MMP3 marker as a potential biomarker for cancer. It has been proven to be a prognostic as well as diagnostic biomarker for certain cancers such as the head and neck squamous-cell carcinoma. Furthermore, this biomarker has been shown to be highly specific for the cancer cell line MMP23.
There are many molecular tests that can be used to determine various medical specialties. For example, human leukocyte antigen typing examines immune function. Molecular diagnostics can also be used in coagulation, pharmacogenomics and a variety of other areas. One example is using microarray chips. These chips contain DNA that is complementary to the sample and emits light when mixed with an experiment.
The use of Molecular Diagnostics is the application of genomic technologies that aid in the diagnosis, subclassification, and prognosis of a range of diseases. The field of molecular diagnostics is a significant area of clinical pathology which has expanded from the simple morphologic observation of cells and tissues to include immunohistochemical, histological and molecular assessments. The pathology department at Yale continues to translate cutting-edge techniques into clinical tests and techniques.
Recent research has demonstrated that MMP3 gene variants are associated with breast-cancer risk. These variants can be used to screen for breast cancer risk and assist doctors to tailor treatment. The research suggests that MMP3 could also be used to delay the progress of the disease. The future of personalized medicine relies on the development of genetic biomarkers that could determine the rate of progression of disease. This breakthrough is a significant step towards personalized medicine.
The MMP3 gene is located on chromosome 11q22.3. It has been implicated in many solid cancers. Its promoter contains a nucleotide sequence that is polymorphic at 1171, which is responsible for different length polymonomeric tracks of Adenosines. Studies have revealed that the promoter activity of the 5A variant is twofold higher than that of the 6A allele.
In addition to its role in the formation of aortic plaques MMP3 also plays an important role in the development of coronary arteries that are calcified. In addition, increased MMP3 expression in coronary artery plaques has been linked with the incidence of myocardial ischemia. Research that focused on the genetic variation of MMP3 gene expression have revealed an unquestionably strong correlation between people who have the 5A/5A genotype and cardiovascular risk.
The results of the COVID-19 study revealed a significant difference of MMP3 levels in serum of healthy people compared to COVID-19-infected people. They also discovered a positive correlation between the two groups. A variety of studies have also examined the importance of MMP3 in lung cancer and respiratory diseases. It is important to comprehend the implications of this new coronavirus strain for people all over the world.
The MMP3 marker can be utilized to determine the MMP levels in an individual sample. It is highly precise. The marker, also known by the acronym act-MMP-3, is of clinical significance even at low levels. This is the first time act-MMP has been extracted from tissue samples and quantified with SDS-PAGE. Loats Associates, Inc. used an Amersham RAS 3000 Image Analysis System to perform the study.
NPC is a type of squamous cell cancer. Both Western Blot and MMP3 markers can be used to diagnose it. To detect tumor cells the MMP3 protein can also be expressed molecularly. The levels of MMP3 do not correlate with clinicopathological variables like the presence or absence of EA and ECV antibodies. However they do have a significant correlation with the clinical stage and lymphoid nodal status.
Two methods were used for the determination of the TIMP and MMP protein. Both methods utilized conditioned media containing the same amount of cell culture media as well as the same protein content and the exact number of cells. The sample was electrophoresed for 4degC. The membrane was then incubated for 30 minutes with 0.1 percent Tween-20-based tris-buffered, tris-buff. The membrane was then incubated at least 30 minutes with the samples.
The SMP300 was made by R&D systems and used to measure the protein concentration in serum. It was added to 96-well plates using DMEM without FBS. After two hours the media that was conditioned was collected and divided into plates with 96 wells for assay. A 96-well plate was filled containing 15 mL NFF-3 stock solution, 300mL of media, and 96 well plates. Each well was then conditioned with media. The final concentration was 16.75 mg/mol. The test results were monitored using a multi-well plate fluorimeter.
A blot analysis of NPC tissue with the MMP3 protein revealed that MMP3 was present in all 15 NPC tissues. This includes stroma and nests of cancerous cells. MMP3 staining was more evident in normal nasopharyngeal epithelial cells and hyperplasia with atypical characteristics. The MMP3 protein is found within the cell membrane and is widely dispersed throughout the cytoplasm.
Recent studies have indicated that serum levels of the MMP3 marker are related to disease severity and response to chemotherapy, but relationships with other systemic biomarkers have not been fully characterised. However, SAA has been linked to the development of atherosclerosis as well in the development of premature cardiovascular disease. In spite of the lack of data regarding its role in these diseases, this marker has attracted considerable attention.
The current research suggests that local MMP levels and histological changes in the alimentary tract are linked to the presence of inflammation processes. MMP-3 and MMP-9 which are metalloproteinases implicated in inflammatory bowel diseases, have been observed to be elevated in patients who suffer from inflammatory bowel disease as compared to healthy individuals. Furthermore, Meijer et al. Meijer et.al.
The MMP-3 level in the serum is associated with systemic inflammation and erosive state in patients suffering from early-stage rheumatoid arthritis. These findings support the idea that this marker is a biomarker that reflects the disease activity. It is interesting that serum MMP-3 has a correlation with synovium MMP-3. This makes it a useful biomarker for inflammation. It is also linked to the balance of MMPs as well as TIMPs.
Clinical applications. MMP3 is a promising marker to predict the severity of rejection. When combined with biopsy results serum MMP3 levels can be used to determine the degree of rejection. This test can be useful in many ways, and it can be used to complement biopsy results. It isn't yet widely accessible. It is still under development. It is necessary to further explore its clinical significance.
PMID: 3360803 by Saus J., et al. The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin.
PMID: 3030290 by Whitham S.E., et al. Comparison of human stromelysin and collagenase by cloning and sequence analysis.
*Showing only the more recent 20. More publications can be found for each product on its corresponding product page